ILC3 inhibits Osteoclastogenesis and ameliorates Inflammatory Bone Loss in Post-menopausal Osteoporosis
This study demonstrates that ILC3s inhibit RANKL-mediated osteoclastogenesis in an IL-2 dependent manner.